A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP MULTICENTER TRIAL OF CVL-865 AS ADJUNCTIVE THERAPY IN ADULTS WITH DRUG-RESISTANT FOCAL ONSET SEIZURES (REALIZE TRIAL)

Brief description of study

The purpose of this study is to learn how well an investigational drug (referred to as “study drug”) called CVL-865 works as a possible treatment for epilepsy. An investigational drug is one that has not been approved by the United States Government (Food and Drug Administration or FDA). This research study will compare CVL-865 to a placebo. The placebo looks just like CVL-865, but contains no medicine. During this study, you may get the placebo instead of CVL-865. A placebo is used in research studies to compare the results and side effects of the drug being studied to the results and side effects of taking no medication. This allows us to see if the drug being studied works and what side effects it causes.


Clinical Study Identifier: s19-01805
ClinicalTrials.gov Identifier: NCT04244175
Principal Investigator: Claude Steriade.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.